Akari Therapeutics PLCNASDAQ:AKTXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE3.0056
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.1800/ 2
- Ask / Lots4.6200/ 2
- Open / Previous Close--- / 3.0056
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AKTX |
|---|---|---|
| 09:41 ET | 250 | 2.9874 |
| 11:22 ET | 168 | 2.98 |
| 11:44 ET | 400 | 2.855 |
| 12:07 ET | 200 | 2.9799 |
| 12:20 ET | 100 | 2.901822 |
| 12:27 ET | 200 | 2.9 |
| 12:34 ET | 1720 | 2.89 |
| 12:43 ET | 200 | 3.0056 |
Sep 17, 2024
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics, from 8:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 17, 2024 by Dow JonesRob Bazemore Appointed to the Board of Directors of Akari Therapeutics, from 8:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 17, 2024 by Dow JonesPress Release: Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics, from 8:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Akari Therapeutics PLC | 36.5M | -1.0x | --- |
Surrozen Inc | 36.2M | -0.5x | --- |
Protara Therapeutics Inc | 36.9M | -0.6x | --- |
Tempest Therapeutics Inc | 35.8M | -0.9x | --- |
NextCure Inc | 37.8M | -0.6x | --- |
Acurx Pharmaceuticals Inc | 34.9M | -1.9x | --- |
Company Information
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
Contact Information
- Headquarters
- 22 BOSTON WHARF ROAD, FL 7BOSTON, MA, United States 02210
- Phone
- 646-350-0702
- Fax
- 646-843-9352
Executives
- Independent Chairman of the Board
- Raymond Prudo-chlebosz
- Interim President, Interim Chief Executive Officer, Director
- Samir Patel
- Interim Chief Financial Officer
- Wendy Dicicco
- Independent Director
- Robert Bazemore
- Independent Director
- Michael Grissinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 607.2K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.93 |
EPS | $-2.98 |
Book Value | $-0.03 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
